title: Can cancer clinical trials be fixed?
authors.forename: Malorye
authors.initials: M
authors.lastname: Allison
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000068258:Bevacizumab; D001709:Biotechnology; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality; D002986:Clinical Trials as Topic / Q000379:methods; D017277:Drug Approval; D004345:Drug Industry; D005260:Female; D006801:Humans; D008453:Maytansine / Q000031:analogs & derivatives / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy* / Q000401:mortality; D010344:Patient Advocacy; D015996:Survival Rate; D013997:Time Factors; D000068878:Trastuzumab; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D008453:Maytansine; D000068258:Bevacizumab; D000068878:Trastuzumab; D000080044:Ado-Trastuzumab Emtansine